RxDoctor Payments Data

Travis Archuleta, MD

Hematology & Oncology · Pueblo, CONPI 1457335010

Payments from drug & device makers

$4,408in general payments, 2019–2025

Across 20 payments — averaging $220.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$4K
  • AstraZeneca$188
  • Merck$140
  • ADC Therapeutics America, Inc.$125
  • Stemline Therapeutics Inc.$94
  • Puma Biotechnology, Inc.$60
  • plus $301 from 10 others

What the payments were for

  • Food & beverage$80088%
  • Education$9611%
  • Gifts$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,408 in reported general payments places this provider in the 35th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$2,819,831
Medicare patients
509
Services billed
125,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide63$1,219,430
PomalystPomalidomide15$285,105
Lenalidomide22$273,479
CalquenceAcalabrutinib Maleate16$243,118
IbrancePalbociclib14$229,540
VenclextaVenetoclax20$170,991
ImbruvicaIbrutinib13$85,759
Abiraterone Acetate122$80,552
XareltoRivaroxaban37$24,334
Imatinib Mesylate26$14,412
Anastrozole338$7,262
Anagrelide Hcl15$1,591
Hydroxyurea53$1,495
Tamoxifen Citrate40$1,405
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$22$1,219,43063 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$19$285,10515 claims
AstraZenecaCalquence$188$243,11816 claims
PfizerIbrance$57$229,54014 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$40$85,75913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →